T Cell News and Research

Latest T Cell News and Research

ThermoGenesis extends reach of stem cell regenerative medicine market into Asia, Central and South America

ThermoGenesis Corp., a leading supplier of innovative products for processing and storing adult stem cells, announced today that it has signed two new distribution agreements that will further extend its global reach into Asia and Central and South America for its offerings in the bone marrow stem cell regenerative medicine market. The Company has now completed four new distribution agreements in the past 90 days, significantly enhancing its ability to market and sell its products throughout the world.

27 Apr 2010

FDA grants NexMed clearance for HCC Phase 2 trial for PrevOnco

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the U.S. Food & Drug Administration (FDA) has cleared the Company to proceed with the proposed Phase 2 trial of PrevOnco™, its proprietary cancer treatment for patients with advanced, unresectable hepatocellular carcinoma (HCC), or liver cancer. The FDA granted PrevOnco™ orphan drug status in August 2008, and in March 2010, NexMed filed its Investigational New Drug (IND) application for the product candidate.

27 Apr 2010

Popular antidepressants may have beneficial side effects for cardiovascular health: Study

A class of antidepressants known as selective serotonin reuptake inhibitors may provide a boost to cardiovascular health by affecting the way platelets, small cells in the blood involved in clotting, clump together, say researchers at the Loyola University Medical Center in Maywood, Ill.

26 Apr 2010

ERCC1 Analysis guides patient treatment decisions

Moffitt Cancer Center announces steadily growing interest in the ERCC1 Analysis, the first test developed for selecting chemotherapy for Non Small Lung Cancer patients. Each year, more than 200,000 Americans are diagnosed with lung cancer.

26 Apr 2010

Caltech biologists offer new insight into causes of IBD and colon cancer

We are not alone-even in our own bodies. The human gut is home to 100 trillion bacteria, which, for millions of years, have co-evolved along with our digestive and immune systems. Most people view bacteria as harmful pathogens that cause infections and disease. Other, more agreeable, microbes (known as symbionts) have taken a different evolutionary path, and have established beneficial relationships with their hosts.

26 Apr 2010

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

OSI Pharmaceuticals, Inc. announced today that it has completed enrollment in the RADIANT study, a Phase III clinical trial testing Tarceva (erlotinib) as an adjuvant therapy in patients with Stage IB-IIIA non-small cell lung cancer who have undergone surgery and have EGFR-positive tumors.

26 Apr 2010

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and ophthalmology, announced today that the National Cancer Institute has initiated a Phase 1/2 clinical trial of TRC105 therapy for patients with castrate-resistant prostate cancer.

26 Apr 2010

Cytovance Biologics, Selexys Pharmaceutical announce collaboration for Anti-PSGL-1 therapeutic agent

Cytovance Biologics, LLC and Selexys Pharmaceutical Corporation jointly announce an agreement and execution of a Biopharmaceutical Development and Manufacturing collaboration for their Anti-PSGL-1 therapeutic agent. This monoclonal antibody (mAb) is being developed for treatment of inflammation associated with Crohn's disease as a lead indication.

26 Apr 2010

Life Technologies debuts Invitrogen MAGic Sample Processor for addressing reproducibility challenges

Life Technologies Corporation today debuted the life science industry's first benchtop sample preparation system designed to increase productivity while eliminating manual and contamination-related challenges traditionally associated with protein and epigenetic protocols. The Invitrogen MAGic™ Sample Processor enables researchers to cut protocol time in half, dramatically reduce experimental errors, and perform technically challenging experiments in protein purification and epigenetics.

26 Apr 2010

National Securities, MD Becker Partners to host SCIENCE program

National Securities Corporation and MD Becker Partners will host their inaugural Stem Cell Investor & Executive Networking Conference Event on June 1, 2010, from 11:00am to 3:00pm (EDT), at National Securities Corporation Global Headquarters at 120 Broadway, (2nd Floor Conference Center) in New York City.

26 Apr 2010

Nanoviricides become registered trademark under USPTO

NanoViricides, Inc., announced today that the mark "nanoviricides" has now become a registered trademark under the US Patents and Trademarks Office. The mark was entered into the "principal register" of trademarks at the USPTO on April 20, 2010.

26 Apr 2010

BioSante signs Option Agreement to obtain non-exclusive worldwide license for 2A/Furin technology

BioSante Pharmaceuticals, Inc. today announced that it has entered into an Option Agreement with an undisclosed large multi-national pharmaceutical company to obtain a non-exclusive worldwide license for the use of BioSante's 2A/Furin technology in the expression of antibodies.

26 Apr 2010

Researchers synthesize metal compounds that can be effective in treatment of cancer

Scientists from Bochum have managed to accurately determine the location of metal complexes within living cancer cells using Raman microscopy. The researchers have thus gained new insights into the mechanism of action of metal-containing drugs, to which they ascribe great potential capacities, e.g. in the treatment of cancer.

26 Apr 2010

Long telomeres in non-demented adults and seniors associated with poorer memory: Researchers

A team of collaborating researchers from the Swedish universities of Umeå, Stockholm, and Linköping is now publishing data showing that long telomeres in non-demented adults and seniors can be associated with poorer memory.

26 Apr 2010

Odors classified into groups by discrete activity states of neuronal circuits: Scientists

Scientists at the Friedrich Miescher Institute for Biomedical Research (FMI, part of the Novartis Research Foundation), are unraveling how odors are processed by the brain. As they report in Nature, odors in the olfactory brain are classified into groups represented by discrete activity states of neuronal circuits.

26 Apr 2010

New reprogramming strategies needed for production of iPSCs: Study

Scientists may be one step closer to being able to generate any type of cells and tissues from a patient's own cells. In a study that will appear in the journal Nature and is receiving early online release, investigators from the Massachusetts General Hospital Center for Regenerative Medicine (MGH-CRM) and the Harvard Stem Cell Institute (HSCI), describe finding that an important cluster of genes is inactivated in induced pluripotent stem cells (iPSCs) that do not have the full development potential of embryonic stem cells.

26 Apr 2010

Mothers with preeclampsia at reduced risk of developing breast cancer

Preeclampsia is a high blood pressure syndrome in pregnant mothers that is caused when the blood supply in the placenta of the developing baby is restricted. The blood-deprived placenta releases factors that cause the raise in blood pressure in the mother. Doctors have to monitor these women closely and they may be forced to deliver the baby early to protect the mother and the baby. Most women's blood pressure returns to normal levels after they deliver the placenta.

26 Apr 2010

Driving evolution of antibiotic resistance backwards

The use of antibiotics to treat bacterial infections causes a continual and vicious cycle in which antibiotic treatment leads to the emergence and spread of resistant strains, forcing the use of additional drugs leading to further multi-drug resistance.

26 Apr 2010

Symphogen's Sympress II technology demonstrates cost-effective single batch production of rpAb

Symphogen A/S today announced the publication of data in the March 20, 2010 online edition of Molecular Biotechnology by Nielsen LS et al. [epub ahead of print] demonstrating the ability of its Sympress II technology to enable cost-effective production of recombinant polyclonal antibodies (rpAb) and antibody mixtures with batch-to-batch consistency that the Company believes could supply drug product for large indications such as cancer and infectious disease.

26 Apr 2010

New method helps study interactions needed for formation of lipopolysaccharides

Scientists have combined chemistry and biology research techniques to explain how certain bacteria grow structures on their surfaces that allow them to simultaneously cause illness and protect themselves from the body's defenses.

26 Apr 2010

T Cell News and Research

Latest T Cell News and Research

ThermoGenesis extends reach of stem cell regenerative medicine market into Asia, Central and South America

FDA grants NexMed clearance for HCC Phase 2 trial for PrevOnco

Popular antidepressants may have beneficial side effects for cardiovascular health: Study

ERCC1 Analysis guides patient treatment decisions

Caltech biologists offer new insight into causes of IBD and colon cancer

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

Cytovance Biologics, Selexys Pharmaceutical announce collaboration for Anti-PSGL-1 therapeutic agent

Life Technologies debuts Invitrogen MAGic Sample Processor for addressing reproducibility challenges

National Securities, MD Becker Partners to host SCIENCE program

Nanoviricides become registered trademark under USPTO

BioSante signs Option Agreement to obtain non-exclusive worldwide license for 2A/Furin technology

Researchers synthesize metal compounds that can be effective in treatment of cancer

Long telomeres in non-demented adults and seniors associated with poorer memory: Researchers

Odors classified into groups by discrete activity states of neuronal circuits: Scientists

New reprogramming strategies needed for production of iPSCs: Study

Mothers with preeclampsia at reduced risk of developing breast cancer

Driving evolution of antibiotic resistance backwards

Symphogen's Sympress II technology demonstrates cost-effective single batch production of rpAb

New method helps study interactions needed for formation of lipopolysaccharides

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in